Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort - PubMed (original) (raw)

Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort

P W G du Buf-Vereijken et al. QJM. 2004 Jun.

Abstract

Background: Immunosuppressive treatment initiated at an early stage in patients with idiopathic membranous nephropathy (iMN) improves renal survival. Treatment should ideally be restricted to high-risk patients.

Aim: To evaluate the efficacy of a restrictive immunosuppressive treatment strategy for patients with iMN.

Design: Prospective cohort study evaluating a predefined treatment protocol.

Methods: From 1988, we adopted a restrictive treatment strategy: immunosuppressive treatment, mainly consisting of cyclophosphamide and steroids, was advised only in patients with renal insufficiency or severe intolerable nephrotic syndrome. We evaluated this strategy in a large patient cohort. To exclude any bias, we included all adult patients with iMN biopsied in the study period with a serum creatinine (Scr) < 135 micromol/l, a proteinuria > or = 3.0 g/day and/or a serum albumin (Salb) < or = 30 g/l at the time of biopsy. Analysis was according to the intention-to-treat principle.

Results: We studied 69 patients. At the time of biopsy, mean age was 51 years, Scr 90 micromol/l, Salb 23 g/l and proteinuria 6.7 g/day. Average follow-up was 5.5 years. Thus far 33 (48%) patients have received immunosuppressive therapy, mainly because of renal insufficiency (n = 24). Status at the end of follow-up was: complete remission n = 22 (32%), partial remission n = 24 (35%), nephrotic syndrome n = 15 (22%), persistent proteinuria n = 1 (1.4%), ESRD n = 6 (8.7%), death n = 1 (1.4%; due to bladder carcinoma after cyclophosphamide therapy). Patient survival was 100% at 5 and 7 years. Renal survival was 94% at 5 years and 88% at 7 years.

Discussion: In patients with iMN, a restrictive treatment policy assures a favourable prognosis, while preventing exposure to immunosuppressive therapy in >50% of the patients.

PubMed Disclaimer

Cited by

Idiopathic Membranous Nephropathy and Treatment Related Complications.
Uncanin S, Dzemidzic J, Serdarevic N, Muslimovic A, Haskovic D. Uncanin S, et al. Med Arch. 2020 Jun;74(3):228-232. doi: 10.5455/medarh.2020.74.228-232. Med Arch. 2020. PMID: 32801441 Free PMC article.
Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study.
Wang J, Xie Q, Sun Z, Xu N, Li Y, Wang L, Liu S, Xue J, Hao CM. Wang J, et al. BMC Nephrol. 2017 Jul 10;18(1):227. doi: 10.1186/s12882-017-0636-0. BMC Nephrol. 2017. PMID: 28693446 Free PMC article.
Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function.
Chen Y, Tang L, Feng Z, Cao X, Sun X, Liu M, Liu S, Zhang X, Li P, Wei R, Qiu Q, Cai G, Chen X. Chen Y, et al. J Nephrol. 2014 Jun;27(3):307-16. doi: 10.1007/s40620-014-0057-0. Epub 2014 Feb 13. J Nephrol. 2014. PMID: 24523071
Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.
van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. van den Brand JA, et al. J Am Soc Nephrol. 2014 Jan;25(1):150-8. doi: 10.1681/ASN.2013020185. Epub 2013 Sep 12. J Am Soc Nephrol. 2014. PMID: 24029426 Free PMC article.
Treatment of idiopathic membranous nephropathy.
Hofstra JM, Fervenza FC, Wetzels JF. Hofstra JM, et al. Nat Rev Nephrol. 2013 Aug;9(8):443-58. doi: 10.1038/nrneph.2013.125. Epub 2013 Jul 2. Nat Rev Nephrol. 2013. PMID: 23820815 Review.

Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort - PubMed (original) (raw)